Skip to main content
NCBI home page
Frontiers in Cellular and Infection Microbiology logoLink to Frontiers in Cellular and Infection Microbiology
. 2021 Jul 19;11:680665. doi: 10.3389/fcimb.2021.680665

Helminth Coinfection Is Associated With Enhanced Plasma Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Tuberculous Lymphadenitis

Gokul Raj Kathamuthu 1,2,*, Kadar Moideen 1, Kannan Thiruvengadam 2, Rathinam Sridhar 3, Dhanaraj Baskaran 2, Subash Babu 1,4
PMCID: PMC8326810  PMID: 34350132

Abstract

Matrix metalloproteinases (MMPs) are crucial for tissue remodeling and repair and are expressed in diverse infections, whereas tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs. However, the interaction of MMPs and TIMPs in tuberculous lymphadenitis (TBL), an extra-pulmonary form of tuberculosis (EPTB) and helminth (Hel+) coinfection is not known. Therefore, this present study investigates the levels of circulating MMPs (1, 2, 3, 7, 8, 9, 12, 13) and TIMPs (1, 2, 3, 4) in TBL individuals with helminth (Strongyloides stercoralis [Ss], hereafter Hel+) coinfection and without helminth coinfection (hereafter, Hel-). In addition, we have also carried out the regression analysis and calculated the MMP/TIMP ratios between the two study groups. We describe that the circulating levels of MMPs (except MMP-8 and MMP-12) were elevated in TBL-Hel+ coinfected individuals compared to TBL-Hel- individuals. Similarly, the systemic levels of TIMPs (1, 2, 3, 4) were increased in TBL-Hel+ compared to TBL-Hel- groups indicating that it is a feature of helminth coinfection per se. Finally, our multivariate analysis data also revealed that the changes in MMPs and TIMPs were independent of age, sex, and culture status between TBL-Hel+ and TBL-Hel- individuals. We show that the MMP-2 ratio with all TIMPs were significantly associated with TBL-helminth coinfection. Thus, our results describe how helminth infection has a profound effect on the pathogenesis of TBL and that both MMPs and TIMPs could dampen the immunity against the TBL-Hel+ coinfected individuals.

Keywords: extra-pulmonary TB, helminth infection, matrix metalloproteinases, tissue inhibitors of metalloproteinases, Luminex ELISA

Introduction

Tuberculosis (TB) poses a significant public threat and kills nearly 1.2 million individuals globally, with 90% of the infection emerging in developing nations (Sanou et al., 2015; WHO, 2019). Both cellular and humoral immunity are necessary to control Mycobacterium tuberculosis (Mtb) infection. They often require activation of monocytes, macrophages, T cells (particularly IFNγ), B cells, natural killer (NK) cells, and dendritic cells (DC) (Flynn and Chan, 2001; Saunders and Britton, 2007; O’Garra et al., 2013). However, during adverse circumstances, Mtb escapes from the protective immune environment or granuloma and thereby advances to different forms of TB such as active pulmonary TB (ATB) and extrapulmonary TB (Russell et al., 2009; O’Garra et al., 2013). Similarly, helminth parasites are well-known multifaceted eukaryotic organisms that cause chronic illness in humans. Strongyloidiasis caused by Strongyloides stercoralis affects about 50-100 million persons worldwide and they exhibit a free-living auto infective cycles followed by prolonged infection (Babu and Nutman, 2013; Puthiyakunnon et al., 2014; Toledo et al., 2015). They are the potential regulators of defensive immunity against different forms of TB (Metenou et al., 2012). Helminth infection usually appears in resource limited settings and accounts for a massive degree of geographical overlap with TB disease (Salgame et al., 2013) and both together cause infection (Allen and Maizels, 2011; O’Garra et al., 2013).

Previous epidemiological and experimental reports have revealed that both systemic and intestinal helminths negatively influence TB disease (Salgame et al., 2013). In addition, both local and systemic inflammatory responses and innate parameters also impact the severity and pathogenesis of TB disease. Most importantly, certain non-specific inflammatory markers like matrix metalloproteinases (MMPs) and acute phase proteins are employed to measure the severity of TB disease and are considered to be an indispensable element (Walzl et al., 2011; Wallis et al., 2013). These MMPs belong to a broad family of zinc- and calcium-dependent proteolytic enzymes. Different studies highlighted the critical role of MMPs in inflammatory cell migration, cellular recruitment, tissue remodeling, destruction of matrix and non-matrix proteins, disease pathogenesis, and immune response alteration (Sundararajan et al., 2012; Bruschi and Pinto, 2013; Ugarte-Gil et al., 2013). MMP activity is regulated by endogenous inhibitors called tissue inhibitors of metalloproteinases (TIMPs). TIMPs are also extremely crucial for the remodeling and repair of normal and pathological tissues following destruction induced by MMPs (Sundararajan et al., 2012; Ugarte-Gil et al., 2013). In pulmonary TB (PTB), MMPs are majorly important in cavitary lung disease and aid in dissemination (Elkington et al., 2011a). Earlier studies have displayed that circulating levels of MMPs were reduced in active TB-helminth coinfected individuals than those with active TB alone (George et al., 2014). Similarly, increased systemic levels of MMPs and TIMPs are the characteristic feature of filarial infection (Anuradha et al., 2012). However, to the best of our knowledge, no studies have reported the circulating levels of MMPs and TIMPs in TBL helminth coinfection. Hence, we examined the same in this study and show that TBL-Hel+ coinfected individuals are associated with enhanced plasma levels of MMPs and TIMPs compared to TBL-Hel- individuals.

Methods

Ethics Statement

The study was sanctioned and approved by the National Institute for Research in Tuberculosis (NIRT)-Institutional Review Board (NIRTIEC2010007), India, and informed written consent was obtained from all the study participants.

Study Subjects

We recruited a group of 88 study participants with TBL disease, among them one group of individuals were infected with Ss infection (n=44, Hel+) and the other group of individuals had only TBL (without Ss infection [Hel-]). The study individuals were well defined and have been reported previously (Kathamuthu et al., 2019). We have utilized the same set of samples in this experiment and their detailed demographics and hematological profile were reported ( Tables 1 , 2 ). TBL individuals were diagnosed based on either histopathology or bacteriological culture using infected lymph node samples. The disease severity was calculated using the homogenized lymph node cultures and calculated based on their grades [0 (no colonies)/1+ (20–100 colonies)/2+(>100 colonies)], which were determined by the growth of Mtb on Lowenstein-Jensen solid media (Mitchison and Aber, 1974). The coinfected individuals had higher severity than the non-coinfected individuals ( Table 1 ). Helminth (Ss) infection was detected by the existence of IgG antibodies to the 31-kDa recombinant NIE antigen (Bisoffi et al., 2014; Buonfrate et al., 2015). The presence of Ss infection was confirmed only using ELISA and not by stool microscopy investigation. The study individuals were anti-tuberculosis and anthelmintic treatment naïve and not affected with any disseminated strongyloidiasis infection. They were all BCG vaccinated and reported negative for filarial infection (based on TropBio ELISA results) and human immune deficiency virus (HIV) infection.

Table 1.

Demographics of the study population.

Study Demographics TBL-Hel+ TBL-Hel- P Value
Number of subjects recruited (n) 44 44 NS
Gender (M/F) 12/32 14/30 NS
Median age in years (range) 23 (18-53) 25 (19-59) NS
Culture grade (0/1+/2+) 7/30/7 15/28/1 0.028 a
NIE IgG antibody titres 484.77 (291-1202) 174.3 (38-281.75) <0.0001b
Open in a new tab

aCalculated using the Chi-square test; NS, Not significant. bCalculated using the Mann-Whitney test.

Table 2.

Hematological profile of the study population.

Hematological profile TBL-Hel+ TBL-Hel- P value a
Whole blood cells (103/litre) 6.01 (4.9-10.9) 6.36 (3.80-11.9) NS
Red blood cells (106/litre) 3.98 (3.94-8.9) 4.14 (3.92-5.44) NS
Lymphocytes (%) 24.53 (14.2-48.1) 28.37 (17.6-43.4) 0.0497
Monocytes (%) 5.20 (2.0-11.7) 7.08 (2.9-20.8) 0.0207
Eosinophils (%) 3.02 (1.6-8.7) 1.70 (1.0-3.2) 0.0316
Basophils (%) 0.85 (0.3-6.7) 0.85 (0.2-2.2) NS
Neutrophils (%) 50.65 (42.9-76.9) 49.77 (45.8-71.6) 0.0287
Platelets (103/litre) 262.13 (152-482) 273.04 (179-654) NS
Hemoglobin (g/dl) 9.7 (8.0-18.3) 11.02 (8.0-14.8) NS
Open in a new tab
a

Calculated using the Mann-Whitney test; NS, Not significant.

Bold values indicates the significance.

Plasma Separation

10 ml of peripheral blood samples were collected in sodium heparin tubes and centrifuged at 2600 revolutions per minute (rpm) for 10 minutes at 4°C. Then the plasma was meticulously transferred in a fresh screw cap vial and stored at -80°C for further use.

Luminex ELISA

The circulating levels of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13 (catalogue number FCSTM07-8), and human TIMP-1, TIMP-2, TIMP-3 and TIMP-4 (catalogue number LKTM003) were measured using a Luminex kit (R&D Systems). The experiments were performed using Bio-Plex® MAGPIX™ multiplex reader (BIO-RAD) and the data were exported using Bio-plex manager 6.1 version.

Statistical Analysis

All the data were analyzed using GraphPad Prism version 8.0 (GraphPad Software Inc., San Diego, CA). Geometric means (GM) were used to measure the central tendency and statistically significant differences between the study groups were analyzed using non-parametric Mann-Whitney U test. Univariate and multivariate (regression) analyses were performed using STATA/MP version 16.0.

Results

TBL-Hel+ Individuals Exhibit Significantly Heightened Circulating Levels of MMPs

To measure the impact of helminth coinfection on TBL disease, we analysed the circulating levels of MMPs (1, 2, 3, 7, 8, 9, 12, 13) in TBL-Hel+ compared to TBL-Hel- individuals ( Figure 1 ). As shown in Figure 1 , the circulating levels of MMP-1 (geometric mean (GM) of Hel+ is 1433 pg/ml vs 1026 pg/ml in Hel-, p=0.0038), MMP-2 (GM of Hel+ is 1750 pg/ml vs 250.8 pg/ml in Hel-, p=0.0043), MMP-3 (GM of Hel+ is 632.2 pg/ml vs 257.5 pg/ml in Hel-, p=0.0379), MMP-7 (Hel+ is 1954 pg/ml vs 1727 pg/ml in Hel-, p=0.0411), MMP-9 (GM of Hel+ is 23691 pg/ml vs 22336 pg/ml in Hel-, p=0.0354) and MMP-13 (Hel+ is 87.75 pg/ml vs 81.81 pg/ml in Hel-, p=0.0074) were significantly elevated in in TBL-Hel+ compared to TBL-Hel- individuals. In contrast, the plasma levels of MMP-8 (Hel+ is 7775 pg/ml vs 7912 pg/ml in Hel-) and MMP-12 (Hel+ is 231 pg/ml vs 228.1 pg/ml in Hel-) were not significantly different between TBL-Hel+ compared to TBL-Hel- individuals. Therefore, TBL-Hel+ coinfection is associated with increased circulating levels of MMPs.

Figure 1.

Figure 1

Open in a new tab

Circulating levels of matrix metalloproteinases (MMPs) were elevated in TBL-Hel+ coinfected individuals. The systemic levels of MMPs (1, 2, 3, 7, 8, 9, 12, 13) were examined in TBL-Hel+ (n = 44) and TBL-Hel- (n = 44) individuals. The results were reported as scatter plots with each circle denoting a single individual. The bar indicates the geometric mean and P values (p < 0.05, *p < 0.01**p < 0.001***p < 0.0001****) were calculated using Mann-Whitney U test.

TBL-Hel+ Individuals Exhibit Significantly Heightened Systemic Levels of TIMPs

To study the effect of helminth coinfection on TBL disease, we examined the plasma levels of TIMPs (1, 2, 3, 4) in TBL-Hel+ and TBL-Hel- individuals ( Figure 2 ). The plasma levels of TIMP-1 (GM of Hel+ is 15072 pg/ml vs 10828 pg/ml in Hel-, p=0.0183), TIMP-2 (GM of Hel+ is 805.1 pg/ml vs 529.8 pg/ml in Hel-, p=0.0403), TIMP-3 (GM of Hel+ is 56.05 pg/ml vs 53.02 pg/ml in Hel-, p=0.0349) and TIMP-4 (GM of Hel+ us 21.54 pg/ml vs 18.30 pg/ml in Hel-, p=0.0239) were significantly elevated in TBL-Hel+ coinfected individuals compared to TBL-Hel- individuals. Thus, heightened circulating levels of TIMPs are the characteristic feature of TBL-Hel+ coinfection.

Figure 2.

Figure 2

Open in a new tab

Circulating levels of tissue inhibitors of metalloproteinases (TIMPs) were elevated in TBL-Hel+ coinfected individuals. The systemic levels of TIMPs (1, 2, 3, 4) were examined in TBL-Hel+ (n = 44) and TBL-Hel- (n = 44) individuals. The results are given as scatter plots with each circle indicating a single individual and the bar representing the geometric mean. P values were calculated using Mann-Whitney U test.

MMP/TIMP Ratio of TBL Helminth Coinfection

We then examined the ratio between MMPs (1, 2, 3, 7, 8, 9, 12, 13) with each of the TIMPs (1, 2, 3, 4) in helminth coinfection with TBL disease compared to TBL-Hel- individuals. As shown in Figure 3 , TBL-Hel+ individuals had significantly altered MMP (1, 2) with TIMP-1, MMP (2) with TIMP-2, MMP (1, 2, 3) with TIMP-3, MMP (1, 2, 3) with TIMP-4 and MMP (3, 7) with TIMP (2, 3) ratio when compared to TBL-Hel- individuals ( Figure 3 ). Thus, MMP-2/TIMP (1, 2, 3, 4) ratios are elevated in TBL-helminth coinfection.

Figure 3.

Figure 3

Open in a new tab

Ratio of MMP/TIMP were altered in TBL-Hel+ coinfected individuals. The ratio of different MMPs (1, 2, 3, 7, 8, 9, 12, 13) and each one of the TIMPs (1, 2, 3, 4) were compared between TBL-Hel+ (n = 44) and TBL-Hel- (n = 44) individuals. The ratios were represented as scatter plots with each circle denoting a single individual and the bar indicating the geometric mean. P values were calculated using Mann-Whitney U test.

Regression Analysis of MMPs and TIMPs

Finally, we examined the univariate and multivariate analysis (with 95% confidence interval [CI]) of MMPs (1, 2, 3, 7, 8, 9, 12, 13) and TIMPs (1, 2, 3, 4) in TBL-Hel+ and TBL-Hel- coinfected individuals upon normalizing the confounding (age, sex and culture status) factors to understand the potential ability to discriminate between the study groups. Our data reveals that MMP-1, MMP-2, and MMP-3 were correlated with the elevated risk of TBL-Hel+ disease. Likewise, among various TIMPs, TIMP-1, TIMP-3, and TIMP-4 were associated with increased risk of TBL-Hel+ disease ( Table 3 ).

Table 3.

Logistic regression model between TBL-Hel+ and TBL-Hel- individuals.

Univariate Multivariate
OR (95% CI) P value *aOR (95% CI) P value
MMP1 2.19 (1.23–3.91) 0.008 2.32 (1.27–4.25) 0.006
MMP2 1.12 (1.03–1.21) 0.005 1.14 (1.05–1.24) 0.003
MMP3 1.21 (1.02–1.43) 0.026 1.23 (1.03–1.46) 0.023
MMP7 2.13 (0.87–5.21) 0.097 2.24 (0.89–5.65) 0.088
MMP8 0.99 (0.76–1.29) 0.940 0.93 (0.69–1.23) 0.596
MMP9 3.18 (0.64–15.69) 0.155 2.45 (0.45–13.34) 0.298
MMP12 1.62 (0.19–14.06) 0.659 1.67 (0.19–14.84) 0.648
MMP13 5.44 (0.87–34.03) 0.070 5.10 (0.74–35.41) 0.099
TIMP1 1.26 (0.86–1.84) 0.232 2.55 (1.20–5.43) 0.015
TIMP2 1.41 (1.01–1.96) 0.045 1.37 (0.98–1.92) 0.064
TIMP3 10.63 (1.01–112.35) 0.049 14.68 (1.24–173.47) 0.033
TIMP4 2.14 (0.94–4.87) 0.070 2.40 (1.02–5.66) 0.046
Open in a new tab

*Multivariate model was adjusted for age, sex and culture status.

Bold values indicates the significance.

Discussion

In TB, MMP levels were increased in peripheral blood and at the site of infection and their systemic levels precisely replicated the disease pathology (Elkington et al., 2011a). In the case of parasitic infections, only a few studies examined the levels of MMPs and TIMPs (Gomez et al., 1999; Tsai et al., 2008; Verma et al., 2011; Maretti-Mira et al., 2011; Geurts et al., 2012). Helminth infections are capable of altering the expression pattern of both MMPs and TIMPs and some of them can act as an activator of these factors (Wynn, 2007; Anuradha et al., 2012). Nevertheless, no studies have explored the role of MMPs and TIMPs in TBL-helminth coinfection specifically in endemic settings for both the disease. Our results reveal that systemic levels of both MMPs (1, 2, 3, 7, 9, 13) and TIMPs (1, 2, 3, 4) were significantly heightened in TBL-Hel+ coinfected pathological situations.

Certain MMPs (1, 2, 3, 9) are associated with enhanced expression and activity upon infection with Mycobacterium tuberculosis (Mtb) (Sathyamoorthy et al., 2015). Previous observations also illustrate that MMPs are higher (1, 2, 3, 8, and 9) in TB infected sputum samples (Ugarte-Gil et al., 2013). Other studies have also shown that various MMPs have been enhanced in TB patients compared to controls (Hoheisel et al., 2001; Elkington et al., 2011b; Sundararajan et al., 2012; Seddon et al., 2013; Sathyamoorthy et al., 2015). The levels of MMPs (1, 2, 8, 9) are increased in pleural fluid of TB patients than non-TB pleuritis (Walker et al., 2012). MMP-9 level was significantly greater in cerebrospinal fluid (CSF) of meningeal TB which associates with their neurological compromise (Matsuura et al., 2000; Price et al., 2001). The levels of MMPs increased in TB-HIV+ coinfected sputum samples when compared to TB-HIV- controls (Walker et al., 2017). Finally, plasma levels of certain MMPs (1, 2, 3, 7, 10, 12 and 13) were significantly increased in TB-diabetes mellitus (DM) coinfected individuals than TB and HC individuals (Kumar et al., 2018). Our data were similar to previous observations and we reveal that systemic levels of MMPs (1, 2, 3, 7, 9, 13) were significantly elevated in TBL-Hel+ coinfected individuals compared to TBL-Hel- individuals. The greater secretion of various MMPs suggests TBL-helminth coinfection could induce extensive degradation of the basement membrane, proteolytic cleavage of tissue matrix, collagen breakdown, and thereby enhances the inflammatory responses in the human host. In addition, the ECM degradation could influence the dissemination of TB infection, which in turn compromises the protective immune responses against TBL infection. Up regulated MMP levels also facilitate the migration of leukocytes into the circulation. This often leads to necrosis and cavitation and thus creates an immune-privileged site for bacterial multiplication. Thus, helminth infection is likely to have detrimental effects on the pathogenesis of TBL disease.

Previous studies have also demonstrated that TIMP-1 and TIMP-2 levels are significantly higher in TB patients than in healthy individuals (Hoheisel et al., 2001; Thrailkill et al., 2009; Puthiyakunnon et al., 2014; Walker et al., 2017; Stek et al., 2018). Similarly, plasma levels of TIMP-1 and TIMP-2 were significantly increased in chronic filarial pathology patients (Anuradha et al., 2012). In contrast, TIMPs (1, 2, 4) levels were significantly diminished and TIMP-3 levels were higher in active TB-Ss+ coinfected individuals (George et al., 2014). Even in TB-Type 2 DM, comorbid patients exhibit higher plasma levels of TIMP-4 but not the other TIMPs when compared to TB disease alone (Andrade et al., 2014). Similarly, our results display that TIMPs (1, 2, 3, 4) were elevated in TBL-Hel+ infected individuals. TIMPs themselves might also be involved in the tissue destruction and hence the TBL-Hel+ infected levels exhibited enhanced TIMPs than the uninfected individuals. In contrast to TBL disease, some of the TIMP levels were reduced in pulmonary TB-helminth coinfection and this is might be because TBL is a more disseminated form than active TB, therefore, tissue destruction could also be higher in those individuals.

Finally, some of the MMPs (1, 2, 3) and TIMPs (2, 3) were linked with an elevated risk of TBL-Hel+ coinfection whereas other markers are negatively associated with enhancing the risk of TBL-helminth coinfection. In addition, TBL-Hel+ individuals had significantly elevated ratios of MMP (1, 2, 3) with all TIMPs and significantly lower ratios of MMP (3, 7) with TIMPs. The possible reason for lower MMP3/TIMP2 and MMP7/TIMP3 ratio might be because they have been reported to be mostly associated with tissue destruction and activation upon TB infection. However, the mechanism involved in the significant increase in the systemic levels of MMPs and TIMPs upon TBL-helminth coinfection requires additional study.

Our study has certain limitations from being a cross sectional study and not being able to include the helminth infected individuals for comparison. Our future studies will examine the pro-inflammatory (IFN-γ, IL-6, IL-12) and anti-inflammatory (IL-4, IL-5, IL-10, TGFβ) cytokines to understand their role in stimulating MMPs and TIMPs in the coinfected groups. Overall, our data precisely display the importance of MMPs and TIMPs in TBL-helminth coinfection and their elevated levels potentially increase the risk of disease or compromise protective immunity against TBL disease. Hence, finding the potential inhibitory molecules for MMPs and TIMPs might be important and can be considered as an adjunct therapy for treating TB and TB-helminth coinfections.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author Contributions

Conceived and designed the experiments: GK and SB. Performed the experiments: GK, KM, and KT. Analyzed the data: GK. Contributed materials/reagents/analysis tools: DB, RS, and SB. Wrote the paper: GK and SB. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors thank V. Rajesh Kumar of NIH-NIRT-ICER and the staff of the Department of Clinical Research, NIRT, Government Stanley Hospital, Government General Hospital, and the Government Kilpauk Medical Hospital in Chennai, India, for valuable assistance in recruiting the patients for this study.

References

  1. Allen J. E., Maizels R. M. (2011). Diversity and Dialogue in Immunity to Helminths. Nat. Rev. Immunol. 11 (6), 375–388.   10.1038/nri2992 [DOI] [PubMed] [Google Scholar]
  2. Andrade B. B., Kumar N. P., Sridhar R., Banurekha V. V., Jawahar M. S., Nutman T. B., et al. (2014). Heightened Plasma Levels of Heme Oxygenase-1 and Tissue Inhibitor of Metalloproteinase-4 as Well as Elevated Peripheral Neutrophil Counts are Associated With TB-Diabetes Comorbidity. Chest 145 (6), 1244–1254.   10.1378/chest.13-1799 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anuradha R., George J. P., Pavankumar N., Kumaraswami V., Nutman T. B., Babu S. (2012). Altered Circulating Levels of Matrix Metalloproteinases and Inhibitors Associated With Elevated Type 2 Cytokines in Lymphatic Filarial Disease. PloS Negl. Trop. Dis. 6 (6), e1681.   10.1371/journal.pntd.0001681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. WHO Global Tuberculosis Report 2019. Available at: https://www.who.int/tb/publications/global_report/tb19_Exec_Sum_12Nov2019.pdf?ua=1.
  5. Babu S., Nutman T. B. (2013). Immunology of Lymphatic Filariasis. Parasite Immunol. 36 (8), 338–436.   10.1111/pim.12081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bisoffi Z., Buonfrate D., Sequi M., Mejia R., Cimino R. O., Krolewiecki A. J., et al. (2014). Diagnostic Accuracy of Five Serologic Tests for Strongyloides Stercoralis Infection. PloS Negl. Trop. Dis. 8 (1), e2640.   10.1371/journal.pntd.0002640 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bruschi F., Pinto B. (2013). The Significance of Matrix Metalloproteinases in Parasitic Infections Involving the Central Nervous System. Pathogens 2 (1), 105–129.   10.3390/pathogens2010105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Buonfrate D., Sequi M., Mejia R., Cimino R. O., Krolewiecki A. J., Albonico M., et al. (2015). Accuracy of Five Serologic Tests for the Follow Up of Strongyloides Stercoralis Infection. PloS Negl. Trop. Dis. 9 (2), e0003491.   10.1371/journal.pntd.0003491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Elkington P. T., Ugarte-Gil C. A., Friedland J. S. (2011. a). Matrix Metalloproteinases in Tuberculosis. Eur. Respir. J. 38, 456–464.   10.1183/09031936.00015411 [DOI] [PubMed] [Google Scholar]
  10. Elkington P., Shiomi T., Breen R., Nuttall R. K., Ugarte-Gil C. A., Walker N. F., et al. (2011. b). MMP-1 Drives Immunopathology in Human Tuberculosis and Transgenic Mice. J. Clin. Invest. 121 (5), 1827–1833.   10.1172/JCI45666 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Flynn J. L., Chan J. (2001). Immunology of Tuberculosis. Annu. Rev. Immunol. 19, 93–129. 10.1146/annurev.immunol.19.1.93 [DOI] [PubMed] [Google Scholar]
  12. George P. J., Kumar N. P., Sridhar R., Hanna L. E., Nair D., Banurekha V. V., et al. (2014). Coincident Helminth Infection Modulates Systemic Inflammation and Immune Activation in Active Pulmonary Tuberculosis. PloS Negl. Trop. Dis. 8 (11), e3289.   10.1371/journal.pntd.0003289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Geurts N., Opdenakker G., Van den Steen P. E. (2012). Matrix Metalloproteinases as Therapeutic Targets in Protozoan Parasitic Infections. Pharmacol. Ther. 133 (3), 257–279.   10.1016/j.pharmthera.2011.11.008 [DOI] [PubMed] [Google Scholar]
  14. Gomez D. E., De Lorenzo M. S., Alonso D. F., Andrade Z. A. (1999). Expression of Metalloproteinases (MMP-1, MMP-2, and MMP-9) and Their Inhibitors (TIMP- 1 and TIMP-2) in Schistosomal Portal Fibrosis. Am. J. Trop. Med. Hyg. 61 (1), 9–13.   10.4269/ajtmh.1999.61.9 [DOI] [PubMed] [Google Scholar]
  15. Hoheisel G., Sack U., Hui D. S., Huse K., Chan K. S., Chan K. K., et al. (2001). Occurrence of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Tuberculous Pleuritis. Tuberculosis (Edinb) 81 (3), 203–209.   10.1054/tube.2000.0276 [DOI] [PubMed] [Google Scholar]
  16. Kathamuthu G. R., Munisankar S., Sridhar R., Baskaran D., Babu S. (2019). Helminth Mediated Modulation of the Systemic and Mycobacterial Antigen – Stimulated Cytokine Profiles in Extra- Pulmonary Tuberculosis. PloS Negl. Trop. Dis. 13 (3), e0007265.   10.1371/journal.pntd.0007265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kumar N. P., Moideen K., Viswanathan V., Shruthi B. S., Sivakumar S., Menon P. A., et al. (2018). Elevated Levels of Matrix Metalloproteinases Reflect Severity and Extent of Disease in Tuberculosis-Diabetes Co-Morbidity and are Predominantly Reversed Following Standard Anti-Tuberculosis or Metformin Treatment. BMC Infect. Dis. 18, 345. 10.1186/s12879-018-3246-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Maretti-Mira A. C., de Pinho Rodrigues K. M., de Oliveira-Neto M. P., Pirmez C., Craft N. (2011). MMP-9 Activity is Induced by Leishmania Braziliensis Infection and Correlates With Mucosal Leishmaniasis. Acta Trop. 119 (2-3), 160–164.   10.1016/j.actatropica.2011.05.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Matsuura E., Umehara F., Hashiguchi T., Fujimoto N., Okada Y., Osame M. (2000). Marked Increase of Matrix Metalloproteinase 9 in Cerebrospinal Fluid of Patients With Fungal or Tuberculous Meningoencephalitis. J. Neurol. Sci. 173 (1), 45–52.   10.1016/S0022-510X(99)00303-2 [DOI] [PubMed] [Google Scholar]
  20. Metenou S., Babu S., Nutman T. B. (2012). Impact of Filarial Infections on Coincident Intracellular Pathogens: Mycobacterium Tuberculosis and Plasmodium Falciparum . Curr. Opin. HIV AIDS 7 (3), 231–238.   10.1097/COH.0b013e3283522c3d [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mitchison D. A., Aber V. R. (1974). Culture of Specimens Other Than Sputum for Mycobacteria. J. Clin. Pathol. 27 (11), 883–887.   10.1136/jcp.27.11.883 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. O’Garra A., Redford P. S., McNab F. W., Bloom C. I., Wilkinson R. J., Berry M. P. (2013). The Immune Response in Tuberculosis. Annu. Rev. Immunol. 31, 475–527.   10.1146/annurev-immunol-032712-095939 [DOI] [PubMed] [Google Scholar]
  23. Price N. M., Farrar J., Tran T. T., Nguyen T. H., Tran T. H., Friedland J. S. (2001). Identification of a Matrix-Degrading Phenotype in Human Tuberculosis in-Vitro and in-Vivo. J. Immunol. 166 (6), 4223–4230.   10.4049/jimmunol.166.6.4223 [DOI] [PubMed] [Google Scholar]
  24. Puthiyakunnon S., Boddu S., Li Y., Zhou X., Wang C., Li J., et al. (2014). Strongyloidiasis-an Insight Into Its Global Prevalence and Management. PloS Negl. Trop. Dis. 8 (8), e3018.   10.1371/journal.pntd.0003018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Russell D. G., Cardona P. J., Kim M. J., Allain S., Altare F. (2009). Foamy Macrophages and the Progression of the Human Tuberculosis Granuloma. Nat. Immunol. 10 (9), 943–948.   10.1038/ni.1781 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Salgame P., Yap G. S., Gause W. C. (2013). Effect of Helminth-Induced Immunity on Infections With Microbial Pathogens. Nat. Immunol. 14 (11), 1118–1126.   10.1038/ni.2736 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sanou A., Bañuls A. L., Van Anh N. T., Godreuil S. (2015). Mycobacterium Tuberculosis: Ecology and Evolution of a Human Bacterium. J. Med. Microbiol. 64 (11), 1261–1269.   10.1099/jmm.0.000171 [DOI] [PubMed] [Google Scholar]
  28. Sathyamoorthy T., Sandhu G., Tezera L. B., Thomas R., Singhania A., Woelk C. H., et al. (2015). Gender-Dependent Differences in Plasma Matrix Metalloproteinase-8 Elevated in Pulmonary Tuberculosis. PloS One 10 (1), e0117605.   10.1371/journal.pone.0117605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Saunders B. M., Britton W. J. (2007). Life and Death in the Granuloma: Immunopathology of Tuberculosis. Immunol. Cell Biol. 85 (2), 103–111.   10.1038/sj.icb.7100027 [DOI] [PubMed] [Google Scholar]
  30. Seddon J., Kasprowicz V., Walker N. F., Yuen H. M., Sunpath H., Tezera L., et al. (2013). Procollagen III N-Terminal Propeptide and Desmosine are Released by Matrix Destruction in Pulmonary Tuberculosis. J. Infect. Dis. 208 (10), 1571–1579.   10.1093/infdis/jit343 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Stek C., Allwood B., Walker N. F., Wilkinson R. J., Lynen L., Meintjes G. (2018). The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy. Front. Microbiol. 9, 2603.   10.3389/fmicb.2018.02603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sundararajan S., Babu S., Das S. D. (2012). Comparison of Localized Versus Systemic Levels of Matrix Metalloproteinases (Mmps), its Tissue Inhibitors (Timps) and Cytokines in Tuberculous and non-Tuberculous Pleuritis Patients. Hum. Immunol. 73 (10), 985–991.   10.1016/j.humimm.2012.07.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thrailkill K. M., Clay Bunn R., Fowlkes J. L. (2009). Matrix Metalloproteinases: Their Potential Role in the Pathogenesis of Diabetic Nephropathy. Endocrine 35 (1), 1–10.   10.1007/s12020-008-9114-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Toledo R., Munoz-Antoli C., Esteban J. G. (2015). Strongyloidiasis With Emphasis on Human Infections and its Different Clinical Forms. Adv. Parasitol. 88, 165–241.   10.1016/bs.apar.2015.02.005 [DOI] [PubMed] [Google Scholar]
  35. Tsai H. C., Chung L. Y., Chen E. R., Liu Y. C., Lee S. S., Chen Y. S., et al. (2008). Association of Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-4 in Cerebrospinal Fluid With Blood-Brain Barrier Dysfunction in Patients With Eosinophilic Meningitis Caused by Angiostrongylus Cantonensis . Am. J. Trop. Med. Hyg. 78 (1), 20–27. 10.4269/ajtmh.2008.78.20 [DOI] [PubMed] [Google Scholar]
  36. Ugarte-Gil C. A., Elkington P., Gilman R. H., Coronel J., Tezera L. B., Bernabe-Ortiz A., et al. (2013). Induced Sputum MMP-1, -3 & -8 Concentrations During Treatment of Tuberculosis. PloS One 8 (4), e61333.   10.1371/journal.pone.0061333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Verma A., Prasad K. N., Nyati K. K., Singh S. K., Singh A. K., Paliwal V. K., et al. (2011). Association of MMP-2 and MMP-9 With Clinical Outcome of Neurocysticercosis. Parasitology. 138, 1423–1428.   10.1017/S0031182011001259 [DOI] [PubMed] [Google Scholar]
  38. Walker N. F., Clark S. O., Oni T., Andreu N., Tezera L., Singh S., et al. (2012). Doxycycline and HIV Infection Suppress Tuberculosis-Induced Matrix Metalloproteinases. Am. J. Respir. Crit. Care Med. 185 (9), 989–997.   10.1164/rccm.201110-1769OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Walker N. F., Wilkinson K. A., Meintjes G., Tezera L. B., Goliath R., Peyper J. M., et al. (2017). Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study. Clin. Infect. Dis. 65 (1), 121–132. 10.1093/cid/cix231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wallis R. S., Kim P., Cole S., Hannam D., Andrade B. B., Maeurer M., et al. (2013). Tuberculosis Biomarkers Discovery: Developments, Needs, and Challenges. Lancet Infect. Dis. 13 (4), 362–372.   10.1016/S1473-3099(13)70034-3 [DOI] [PubMed] [Google Scholar]
  41. Walzl G., Ronacher K., Hanekom W., Scriba T. J., Zumla A. (2011). Immunological Biomarkers of Tuberculosis. Nat. Rev. Immunol. 11 (5), 343–354.   10.1038/nri2960 [DOI] [PubMed] [Google Scholar]
  42. Wynn T. A. (2007). Common and Unique Mechanisms Regulate Fibrosis in Various Fibroproliferative Diseases. J. Clin. Invest. 117 (3), 524–529.   10.1172/JCI31487 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Articles from Frontiers in Cellular and Infection Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES